Since then, n-of-1 ASOs have been developed for several other individual patients through accelerated regulatory pathways, including an individualized ASO for a specific ataxia-telangiectasia (AT) mutation (“Atipeksen”) and one for a specific Amyotrophic Lateral Sclerosis (ALS) causing mutation in FUS (“Jacifusen,” named after 26-year-old Jaci Hermstad, diagnosed with FUS-associated ALS in February 2019 and first patient treated with this ASO, which was already under development by Ionis Pharmaceuticals). This evidence concerns the gene FUS and amyotrophic lateral sclerosis.